Skip to main content

turmetabart adizutecan

Generic: Turmetabart Adizutecan

turmetabart adizutecan: 2 clinical trials tracked.

turmetabart adizutecan evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about turmetabart adizutecan, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 1 study sponsors

Related indications

No linked indication is available.

Clinical Trial Registry Records (2)

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC)

NCT07365241Registry updated 2026-09-23·Phase 3·ABBV
Recruiting

Primary endpoint: Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR)

InterventionalRandomizedopen531 targetStarted 2026-07Completion 2030-0950 sites · Austria, Belgium, Brazil, France…AbbVie

A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT07155174Registry updated 2026-10-02·Phase 2·ABBV
Recruiting

Primary endpoint: Number of Participants with Adverse Events (AE)s

InterventionalRandomizedopen180 targetStarted 2025-11Completion 2031-0969 sites · Belgium, China, Germany, Israel…AbbVie